Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 10/20 | 0.36 |
| ▸ | CTSS | P25774 | 7/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7346754 | 1.00 | CA1 (0.38) | CA1CA2CA7ATMCYP2D6 | |
| SCHEMBL4520424 | 1.00 | CA1 (0.38) | CA1CA2CA7ATMCYP2D6 | |
| SCHEMBL1861342 | 0.85 | CA1 (0.40) | CA1CA2CA7ATMCYP2D6 | |
| SCHEMBL1861340 | 0.85 | CA1 (0.40) | CA1CA2CA7ATMCYP2D6 | |
| SCHEMBL3227264 | 0.85 | CA1 (0.40) | CA1CA2CA7ATMCYP2D6 | |
| SCHEMBL9622351 | 0.85 | CTSK (0.36) | CA1CA2CA7ATMCYP2D6 | |
| SCHEMBL3613413 | 0.84 | CA1 (0.39) | CA1CA2CA7ATMCYP2D6 | |
| SCHEMBL3613415 | 0.84 | CA1 (0.39) | CA1CA2CA7ATMCYP2D6 | |
| SCHEMBL211828 | 0.83 | CTSK (0.37) | CA1CA2CA7ATMCYP2D6 | |
| SCHEMBL211829 | 0.83 | CTSK (0.37) | CA1CA2CA7ATMCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119317620-A | Azacycloalkyl carbonyl cyclic amine compounds | 亚力维克希斯股份有限公司 | 2025-01-14 | — | — | CN | disclosed |
| EP-4405353-A1 | NEW COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | F. Hoffmann-La Roche AG (CH) | 2024-07-31 | — | — | EP | disclosed |
| CN-117999261-A | Novel compounds and their use in the treatment of bacterial infections | 豪夫迈·罗氏有限公司 | 2024-05-07 | — | — | CN | disclosed |
| WO-2023041757-A1 | NEW COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2023-03-23 | — | — | WO | disclosed |
| US-7879848-B2 | good inhibition activity versus Dipeptidyl Peptidase-IV (DPP-IV); Diabetes mellitus, obesity; 3-[2S-amino-4-oxo-4-(3-trifluoromethyl-5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-butyl]-oxazolidin-2-one; compounds having an optionally substituted lactam ring structure | LG LIFE SCIENCES, LTD. (KR) | 2011-02-01 | — | — | US | disclosed |
| EP-1863812-B1 | DIPEPTIDYL PEPTIDASE-IV INHIBITING COMPOUNDS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES LTD (KR) | 2010-07-14 | — | — | EP | disclosed |
| EP-1863812-A4 | DIPEPTIDYL PEPTIDASE-IV INHIBITING COMPOUNDS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES LTD (KR) | 2009-06-24 | — | — | EP | disclosed |
| US-20080188471-A1 | Dipeptidyl Peptidase-IV Inhibiting Compounds, Method Of Preparing The Same, And Pharmaceutical Compositions Containing The Same As An Active Agent | LG LIFE SCIENCES, LTD. (KR) | 2008-08-07 | — | — | US | disclosed |
| EP-1863812-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITING COMPOUNDS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG Life Sciences Ltd. (KR) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006104356-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITING COMPOUNDS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES, LTD. (KR) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188471-A1 | Dipeptidyl Peptidase-IV Inhibiting Compounds, Method Of Preparing The Same, And Pharmaceutical Compositions Containing The Same As An Active Agent | DPP4, DPP7, DPP8 | CA1 910/4885CA2 764/4885CA7 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.